First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Toshio Shimizu,Jacob Sands,Kiyotaka Yoh,Alexander Spira,Edward B Garon,Satoru Kitazono,Melissa L Johnson,Funda Meric-Bernstam, Anthony W Tolcher,Noboru Yamamoto,Jon Greenberg,Yui Kawasaki,Hong Zebger-Gong,Fumiaki Kobayashi,Penny Phillips,Aaron E Lisberg,Rebecca S Heist

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 2|浏览22

暂无评分

摘要

Promising antitumor activity and a manageable safety profile were seen with Dato-DXd in heavily pretreated patients with advanced NSCLC. Further investigation as first-line combination therapy in advanced NSCLC and as monotherapy in the second-line setting and beyond is ongoing.

查看译文

关键词

lung cancer,first-in-human,dose-escalation,dose-expansion,cell-surface,antibody-drug,small-cell,tropion-pantumor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要